| Fri, 23 Jul 2021 13:08:07: | Novel degrader of cancer-driving protein AKT slows prostate, breast tumors in mice
|
| Fri, 23 Jul 2021 09:37:13: | UPDATE: Half of Adverum pipeline 'snaps out of existence' as adverse events force pivot to more common eye disease
|
| Fri, 23 Jul 2021 08:49:54: | Lumos delays key hormone deficiency readout as COVID bites
|
| Fri, 23 Jul 2021 08:19:52: | Eli Lilly pens pact with Banner Alzheimer's Institute for ‘virtual approach’ for its late-stage donanemab test
|
| Thu, 22 Jul 2021 11:32:12: | Seres Therapeutics’ microbiome therapy flops against placebo as shares go into freefall
|
| Thu, 22 Jul 2021 10:34:30: | Roche in ‘continued dialogue’ with FDA over Alzheimer’s prospect; culls early-stage assets in Q2 clearout
|
| Wed, 21 Jul 2021 18:26:38: | New gene therapy approach shows signs of preventing vision loss from glaucoma
|
| Wed, 21 Jul 2021 13:05:09: | AbbVie, Roche top data transparency list, but more could be done to build trust in medical system: report
|
| Wed, 21 Jul 2021 12:43:45: | Hemab raises $55M to target multiple rare bleeding indications
|
| Wed, 21 Jul 2021 12:16:00: | Vedanta raises $68M, reveals setback to Bristol Myers alliance
|
| Wed, 21 Jul 2021 11:26:06: | Coave raises $25M ahead of pivotal retinal gene therapy trial
|
| Wed, 21 Jul 2021 08:41:42: | Novartis ditches midstage dry eye drug, gets New Year’s PDUFA data for troubled Leqvio
|
| Wed, 21 Jul 2021 08:40:43: | Bayer's drug that turns a cancer-protective pathway toxic eradicates breast tumors in mice
|
| Tue, 20 Jul 2021 13:10:35: | Rivus’ fat-trimming therapy nabs $35M to harness our own biology against a host of diseases
|
| Tue, 20 Jul 2021 11:54:21: | In an unusual crossover, Gilead hires Arcus CMO Grossman, putting him in charge of cancer pact with his former biotech
|
| Tue, 20 Jul 2021 11:28:46: | Panakčs moves into biotech investing with new €150M fund
|
| Tue, 20 Jul 2021 10:48:53: | Ardelyx stock craters as FDA slaps biotech with dreaded ‘deficiencies’ tag on kidney drug
|
| Mon, 19 Jul 2021 12:57:03: | Surprise genetic discovery in macular degeneration points to new treatment strategy
|
| Mon, 19 Jul 2021 12:10:41: | Rome, backed by Arch and GV, hires science leaders to hit targets in “junk DNA”
|
| Mon, 19 Jul 2021 11:24:26: | Adagio seeks IPO to bring COVID-19 antibody to market in 2022
|
| Mon, 19 Jul 2021 09:18:12: | Troubled Cytokinetics' stock soars as gets much needed phase 2 heart drug trial win, plans late-stage effort by year’s end
|
| Fri, 16 Jul 2021 14:30:49: | Regeneron plans $1.8B upgrade at Tarrytown campus, where it aims to add 1,000 new staffers over 5 years
|
| Fri, 16 Jul 2021 10:30:20: | Polyphor sharpens ax on staff, shutters failed breast cancer test
|
| Fri, 16 Jul 2021 09:10:43: | GSK sells off part of its U.K. R&D site to rake in $554M and boost biotech ops
|
| Thu, 15 Jul 2021 21:38:22: | 2 pathways that prepare and kill melanoma cells could inspire novel anti-cancer drugs
|
